Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Somatostatin PA Coverage | Open…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Somatostatins Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity limits for selected somatostatin-related drugs and pegvisomant/paltusotine products in the Boeing commercial formulary. It applies to providers requesting initial or renewal coverage for these agents.

    Policy Summary
    PayerPrime Therapeutics
    PolicySomatostatins Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of preferred-agent history, clinical benefit, specialist involvement, and requested-agent treatment within the past 180 days when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Target brand agents
    12 monthsApproval duration
    180 daysContinuation lookback
    30 daysOral or vial supply

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    28 days
    Depot injectable supply

    Coverage Criteria

    Initial Therapy for Non-Preferred Target Agents

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The requested agent is eligible for continuation of therapy: the prescriber states the patient has been treated with the requested agent within the past 180 days (starting on samples is not approvable) and is at risk if therapy is changed.
      • BOTH of the following

        • The patient has a covered indication for the requested agent.
        • ONE of the following

          • The patient has tried and had an inadequate response to ONE preferred agent. [Chart notes required]
          • The patient has an intolerance or hypersensitivity to ONE preferred agent that is not expected to occur with the requested agent. [Chart notes required]
          • The patient has an FDA-labeled contraindication to ALL preferred agents that is not expected to occur with the requested agent. [Chart notes required]
          • There is support for use of the requested agent over the preferred agent for the requested indication.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Renewal Therapy

    Target agents will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent, such as decreased symptom severity or frequency, reduction in tumor size, or normalized IGF-1 and/or growth hormone levels.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
    • If the requested agent is being used for acromegaly, the patient will NOT use the requested agent in combination with Signifor LAR (pasireotide).
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Mycapssa Initial Therapy

    Mycapssa (octreotide) will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The requested agent is eligible for continuation of therapy: the prescriber states the patient has been treated with the requested agent within the past 180 days (starting on samples is not approvable) and is at risk if therapy is changed.
      • BOTH of the following

        • The patient has a diagnosis of acromegaly.
        • The patient has responded to and tolerated treatment with octreotide or lanreotide.
        • The patient will NOT use the requested agent in combination with Signifor LAR (pasireotide) for the requested indication.

    Covered Indications

    The patient must have ONE of the following covered indications:

    ONE of the following

    • Acromegaly, with inadequate response to surgical resection or pituitary irradiation as indicated by growth hormone and serum IGF-1 above reference ranges, or the patient is not a candidate for surgical resection, or the requested agent will be used in combination with or following pituitary radiation therapy.
    • Flushing and/or diarrhea associated with metastatic carcinoid tumors.
    • Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors.
    • Another FDA-labeled indication for the requested agent and route of administration.
    • Another indication supported in compendia for the requested agent and route of administration.

    Initial Evaluation — General Eligibility

    Initial evaluation: Target agents will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The requested agent is eligible for continuation of therapy: the prescriber states the patient has been treated with the requested agent within the past 180 days (starting on samples is not approvable) and is at risk if therapy is changed.
      • The patient meets an applicable covered-indication pathway.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Initial Therapy — Acromegaly

    For acromegaly, ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The patient had an inadequate response to surgical resection or pituitary radiation therapy, as indicated by growth hormone and serum IGF-1 above reference ranges.
      • The patient is not a candidate for surgical resection.
      • The requested agent will be used in combination with or following pituitary radiation therapy.
    • The patient will NOT use the requested agent in combination with Signifor LAR (pasireotide) for the requested indication.
    • ONE of the following

    Other Labeled or Compendia-Supported Indication

    For another labeled or compendia-supported indication, ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The patient has flushing and/or diarrhea associated with metastatic carcinoid tumors.
      • The patient has profuse watery diarrhea associated with VIP-secreting tumors.
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
      • The patient has another indication supported in compendia for the requested agent and route of administration.
    • If the patient has an FDA-labeled indication, ONE of the following

    Renewal Therapy — General Criteria

    Renewal evaluation: Target agents will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent, such as decreased symptom severity or frequency, reduction in tumor size, or normalized IGF-1 and/or growth hormone levels.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
    • If the requested agent is being used for acromegaly, the patient will NOT use the requested agent in combination with Signifor LAR (pasireotide).

    Brand-Agent Exception

    For a requested brand agent with an available generic equivalent, ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The patient has an intolerance or hypersensitivity to the generic equivalent that is NOT expected to occur with the requested brand agent. [Chart notes required]
      • The patient has an FDA-labeled contraindication to the generic equivalent that is NOT expected to occur with the requested brand agent. [Chart notes required]
      • There is support for use of the requested brand agent over the generic equivalent.
    • The patient has responded to and tolerated Sandostatin (octreotide) for a minimum of 2 weeks.

    Neuroendocrine Tumor and Other Indication Pathways

    The patient must meet the applicable indication pathway:

    ONE of the following

    • Acromegaly: the patient had an inadequate response to surgical resection or pituitary radiation therapy, is not a candidate for surgical resection, or will use the requested agent in combination with or following pituitary radiation therapy; and the requested agent will NOT be used with Signifor LAR.
    • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    • Flushing and/or diarrhea associated with metastatic carcinoid tumors.
    • Profuse watery diarrhea associated with VIP-secreting tumors.
    • Another FDA-labeled indication for the requested agent and route of administration.

    Initial Evaluation

    Initial evaluation: Target agents will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The requested agent is the preferred agent.
      • The requested agent is non-preferred AND ALL of the following

        • ONE of the following

          • For a 60 mg or 90 mg strength used to treat acromegaly, the patient is initiating therapy with the requested agent.
          • For a 60 mg or 90 mg strength used to treat acromegaly, the patient is titrating the dose based on IGF-1/GH levels and/or clinical symptoms, and there is support for why the patient cannot use the 120 mg preferred agent.

    Non-Preferred Agent Criteria

    For a non-preferred agent, ALL applicable criteria are met:

    ALL of the following

    • ONE of the following

      • The patient tried and had an inadequate response to ONE preferred agent for the requested indication. [Chart notes required]
      • The patient has an intolerance or hypersensitivity to ONE preferred agent that is NOT expected to occur with the requested agent. [Chart notes required]
      • The patient has an FDA-labeled contraindication to ALL preferred agents that is NOT expected to occur with the requested agent. [Chart notes required]
      • The patient is currently using a preferred agent for the requested indication and the requested agent will be used as add-on (adjunctive) therapy.

    Renewal Evaluation

    Renewal evaluation: Target agents will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent, such as decreased symptom severity or frequency, reduction in tumor size, or normalized IGF-1 and/or growth hormone levels.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
    • If the requested agent is being used for acromegaly, the patient will NOT use the requested agent in combination with Signifor LAR (pasireotide).
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Quantity-Limit Criteria

    The requested quantity will be approved when ONE of the following is met:

    ONE of the following

    • The requested quantity or dose does NOT exceed the program quantity limit.
    • ALL of the following

      • The requested quantity or dose exceeds the program quantity limit.
      • ONE of the following

        • ALL of the following

          • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.

    The requested agent will NOT be approved for use in combination with Signifor LAR (pasireotide) when used for acromegaly.

    The patient must not have any FDA-labeled contraindications to the requested agent.

    For acromegaly, the requested agent will NOT be approved when used in combination with Signifor LAR (pasireotide).

    The patient must not have any FDA-labeled contraindications to the requested agent.

    Treatment initiated with samples does not establish eligibility for continuation of therapy. The prescriber must state that the patient has been treated with the requested agent within the past 180 days and is at risk if therapy is changed.

    The requested agent will NOT be approved for use in combination with Signifor LAR (pasireotide) when used for acromegaly.

    The patient must not have any FDA-labeled contraindications to the requested agent.

    Initial Therapy Criteria

    Initial Therapy

    Initial approval requires a qualifying continuation or indication pathway, preferred-agent criteria when applicable, specialist involvement, and no contraindication.

    Initial therapy: The request meets a qualifying clinical indication or continuation pathway; the patient meets the preferred-agent step-therapy or exception requirement when the requested agent is non-preferred; the prescriber is a relevant specialist or has consulted one; and the patient has no FDA-labeled contraindication to the requested agent.

    Approval length is 12 months. Quantity limits apply when specified.

    Mycapssa Initial Therapy

    Mycapssa initial therapy requires all of the following.

    Mycapssa initial therapy: The patient qualifies through continuation, acromegaly after response to and tolerance of octreotide or lanreotide, another FDA-labeled indication and route, or a compendia-supported indication and route; the prescriber is a relevant specialist or has consulted one; and the patient has no FDA-labeled contraindication to Mycapssa.

    For acromegaly, Mycapssa must not be used with Signifor LAR. Approval length is 12 months.

    Continuation and Renewal Criteria

    Continuation and Renewal

    All target agents are eligible for continuation; renewal requires all listed conditions.

    Continuation and renewal: The patient has been treated with the requested agent within the past 180 days and is at risk if therapy is changed, or was previously approved through the plan's prior authorization process; the patient has clinical benefit; the prescriber is a relevant specialist or has consulted one; the requested agent is not combined with Signifor LAR for acromegaly; and there is no FDA-labeled contraindication to the requested agent.180 days; 12-month approval

    Starting therapy with samples does not qualify for continuation. Clinical benefit can include symptom improvement, tumor-size reduction, or normalized IGF-1/growth hormone levels.

    Continuation of Therapy

    All target agents are eligible for continuation of therapy when the prescriber states that the patient has been treated with the requested agent within the past 180 days and is at risk if therapy is changed.

    Continuation eligibility:

    Preferred-Agent and Brand Step Requirements

    StepRequirementQualifying exceptions or documentation
    1Try one preferred agent before the requested non-preferred agent.The requirement may be met with documented inadequate response to one preferred agent, intolerance or hypersensitivity to one preferred agent, an FDA-labeled contraindication to all preferred agents, or support for using the requested agent over the preferred agent.
    StepRequirementDocumentation
    1For Mycapssa used for acromegaly, the patient must have responded to and tolerated octreotide or lanreotide.Document the prior treatment response and tolerance. Mycapssa must not be used with Signifor LAR for the requested indication.
    StepRequirementQualifying exceptions or documentation
    1For acromegaly, try one preferred agent before the requested agent.The requirement may be met with documented inadequate response to one preferred agent, intolerance or hypersensitivity to one preferred agent, an FDA-labeled contraindication to all preferred agents, or inadequate response to another somatostatin analog, such as Bynfezia, Somavert, Somatuline Depot/lanreotide, or Sandostatin LAR. Chart notes are required for the applicable preferred-agent pathways.
    StepRequirementDocumentation
    2For the applicable brand pathway, the patient must have responded to and tolerated Sandostatin (octreotide).Treatment must be documented for a minimum of 2 weeks. The brand-over-generic exception must also be met when a generic equivalent is available.
    StepRequirementQualifying exceptions or documentation
    1Try a preferred agent before the requested non-preferred agent.The requirement may be met with documented inadequate response, intolerance or hypersensitivity, an FDA-labeled contraindication, current preferred-agent use with the requested agent as adjunctive therapy, or support for using the requested agent over all preferred agents. For applicable acromegaly dosing, a rationale may also be required for using a non-preferred strength instead of the preferred 120 mg every 6 to 8 weeks.

    Drug Quantity Limits

    Bynfezia Pen quantity limit
    ProductBynfezia Pen (octreotide acetate solution pen-injector 2500 mcg/mL)
    Quantity limit2 pens
    Day supply30 days
    Lanreotide acetate / Somatuline Depot 120 mg quantity limit
    ProductLanreotide acetate / Somatuline Depot 120 mg/0.5 mL
    Quantity limit1 syringe
    Day supply28 days

    Provider Submission and Authorization Actions

    Prior Authorization

    Initial Non-Preferred Agent Approval

    Submit an initial prior authorization request showing that the requested non-preferred agent meets the applicable indication, step-therapy or exception, specialist, and safety requirements.

    • Document a qualifying FDA-labeled or compendia-supported indication.
    • Document preferred-agent failure, intolerance, contraindication, or support for using the requested agent over the preferred agent.
    Documentation Required

    Continuation Eligibility

    For continuation requests, state that the patient has been treated with the requested agent within the past 180 days; treatment initiated with samples is not approvable, and the patient must be at risk if therapy is changed.

    • All target agents are eligible for continuation of therapy when these requirements are met.

    Operational Dosing and Continuation Parameters

    Continuation lookback
    Lookback periodThe patient must have been treated with the requested agent within the past 180 days.
    Risk requirementThe patient must be at risk if therapy is changed.
    SamplesTreatment started with samples does not qualify for continuation.
    Preferred extended-interval dosing
    Preferred strength120 mg
    Extended intervalEvery 6 to 8 weeks
    When an alternative is requestedSupport is required when titrating or remaining stable on 60 mg or 90 mg instead of switching to the preferred 120 mg extended-interval dosing.

    Policy Definitions

    Compendia allowed
    AHFSRecommended use is allowed.
    NCCNLevel 1, 2a, or 2b recommended use is allowed.
    DrugDexLevel 1, 2a, or 2b evidence is allowed.
    Continuation of therapy
    Eligible agentsAll target agents are eligible for continuation of therapy.
    Recent treatmentThe requested agent must have been used within the past 180 days.
    Change riskThe patient must be at risk if therapy is changed; treatment started with samples is not approvable for continuation.

    Policy Background

    This policy addresses prior authorization and quantity limits for selected somatostatin-related therapies, as well as related agents used for conditions including acromegaly, gastroenteropancreatic neuroendocrine tumors, carcinoid-tumor-associated flushing or diarrhea, and profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumors. Review considers the qualifying indication, prior treatment response, clinical or tumor outcomes, endocrine laboratory findings, specialist involvement, and the absence of contraindications. Coverage may be supported by an applicable FDA-labeled indication or specified compendia support for the requested agent and route of administration.

    Policy Summary
    PayerPrime Therapeutics
    PolicySomatostatins Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of preferred-agent history, clinical benefit, specialist involvement, and requested-agent treatment within the past 180 days when applicable.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Renewal CriteriaPreferred-Agent and Brand Step RequirementsDrug Quantity LimitsProvider Submission and Authorization ActionsOperational Dosing and Continuation ParametersPolicy DefinitionsPolicy Background
  1. The patient has another FDA-labeled indication for the requested agent and route of administration.
  2. The patient has another indication supported in compendia for the requested agent and route of administration.
  3. The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
  4. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  5. The patient tried and had an inadequate response to ONE preferred agent. [Chart notes required]
  6. The patient has an intolerance or hypersensitivity to ONE preferred agent. [Chart notes required]
  7. The patient has an FDA-labeled contraindication to ALL preferred agents. [Chart notes required]
  8. The patient tried and had an inadequate response to another somatostatin analog agent, such as Bynfezia, Somavert, Somatuline Depot/lanreotide, or Sandostatin LAR.
  9. The patient's age is within FDA labeling for the requested indication and agent.
  10. There is support for use of the requested agent for the patient's age and indication.
  11. The patient does NOT have any FDA-labeled contraindications to the requested agent.
    The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
  12. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  13. Another indication supported in compendia for the requested agent and route of administration.
    For a 60 mg or 90 mg strength used to treat acromegaly, the patient is stable on that strength and there is support for why the patient cannot switch to extended-interval dosing with the 120 mg preferred agent every 6 to 8 weeks.
  14. The patient tried and had an inadequate response to a preferred agent. [Chart notes required]
  15. The patient has an intolerance or hypersensitivity to a preferred agent that is NOT expected to occur with the requested agent. [Chart notes required]
  16. The patient has an FDA-labeled contraindication to the preferred agent that is NOT expected to occur with the requested agent. [Chart notes required]
  17. The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist or oncologist, or the prescriber has consulted with a specialist in that area.
  18. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  19. There is support for use of the requested agent over ALL preferred agents for the requested indication.
  20. For a 60 mg or 90 mg strength used to treat acromegaly, the patient is initiating therapy, titrating based on IGF-1/GH levels or clinical symptoms with support for not using the 120 mg preferred agent, or is stable with support for not switching to 120 mg extended-interval dosing.
  21. The patient will NOT use the requested agent in combination with Signifor LAR (pasireotide) for the requested indication.
  22. There is support for therapy with a higher dose for the requested indication.
  23. ALL of the following

    • The requested quantity or dose does NOT exceed the maximum FDA-labeled dose for the requested indication.
    • There is support for why the requested quantity or dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  24. ALL of the following

    • The requested quantity or dose exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  25. Initial Evaluation

    Initial therapy requires either continuation eligibility or a qualifying diagnosis/indication pathway, plus specialist involvement and no contraindication.

    Initial authorization: The request satisfies a continuation-eligibility pathway or qualifying diagnosis/indication pathway; the prescriber is a specialist or has consulted with a specialist; and the patient has no FDA-labeled contraindication to the requested agent.

    The applicable diagnosis-specific requirements must also be met.

    Qualifying Indications

    Diagnosis-specific initial pathways include acromegaly, other labeled or compendia-supported indications, and certain neuroendocrine tumor-related symptoms.

    Diagnosis-specific pathways: Acromegaly with required surgical/radiation and prior-agent criteria; another FDA-labeled indication; a compendia-supported indication; flushing and/or diarrhea associated with metastatic carcinoid tumors; or profuse watery diarrhea associated with VIP-secreting tumors.

    For FDA-labeled indications, age must be within labeling or supported for the requested indication.

    Initial Therapy

    Initial approval requires all applicable general requirements and a qualifying indication.

    General initial requirements: The patient has a qualifying indication, the prescriber is a specialist or has consulted a specialist, the requested agent is appropriate under the preferred/non-preferred rules, and the patient has no FDA-labeled contraindication to the requested agent.

    Acromegaly treatment must not be combined with Signifor LAR.

    Acromegaly Strength and Dosing

    For 60 mg or 90 mg non-preferred dosing for acromegaly, one additional dosing rationale is required.

    Strength-specific exception: The patient is initiating therapy; is titrating based on IGF-1, growth hormone levels, or clinical symptoms with support for not using the preferred 120 mg agent; or is stable on 60 mg or 90 mg with support for not switching to 120 mg every 6 to 8 weeks.60 mg or 90 mg; preferred 120 mg every 6 to 8 weeks

    Applies when the requested agent is non-preferred and used for acromegaly.

    Preferred-Agent Step Criteria

    For non-preferred agents, one preferred-agent exception is required.

    Preferred-agent exception: The patient tried and had an inadequate response to a preferred agent; has intolerance or hypersensitivity to a preferred agent; has an FDA-labeled contraindication to all preferred agents; is currently using a preferred agent and the requested agent will be adjunctive; or there is support for use over all preferred agents.

    Chart notes are required for specified pathways.

    The patient has been treated with the requested agent within the past 180 days and is at risk if therapy is changed.
    Within past 180 days

    Treatment started on samples is not approvable.

    Continuation of Therapy

    All target agents are eligible for continuation of therapy.

    Continuation eligibility: The prescriber states that the patient has been treated with the requested agent within the past 180 days and is at risk if therapy is changed.180 days

    Starting on samples is not approvable.

    Renewal Therapy

    Renewal requires all listed conditions.

    Renewal: The patient has prior plan approval, has experienced clinical benefit, has specialist involvement or consultation, will not use the requested agent with Signifor LAR for acromegaly, and has no FDA-labeled contraindication to the requested agent.

    Clinical benefit examples include reduced symptom severity or frequency, reduced tumor size, and normalized IGF-1 and/or growth hormone levels.

    Mycapssa quantity limit
    ProductMycapssa (octreotide acetate delayed-release 20 mg capsules)
    Quantity limit120 capsules
    Day supply30 days
    Palsonify 20 mg quantity limit
    ProductPalsonify (paltusotine hydrochloride 20 mg tablets)
    Quantity limit60 tablets
    Day supply30 days
    Palsonify 30 mg quantity limit
    ProductPalsonify (paltusotine hydrochloride 30 mg tablets)
    Quantity limit60 tablets
    Day supply30 days
    Sandostatin LAR Depot 10 mg quantity limit
    ProductSandostatin LAR Depot (octreotide acetate IM injection kit 10 mg)
    Quantity limit1 kit
    Day supply28 days
    Sandostatin LAR Depot 20 mg quantity limit
    ProductSandostatin LAR Depot (octreotide acetate IM injection kit 20 mg)
    Quantity limit1 kit
    Day supply28 days
    Sandostatin LAR Depot 30 mg quantity limit
    ProductSandostatin LAR Depot (octreotide acetate IM injection kit 30 mg)
    Quantity limit1 kit
    Day supply28 days
    Somatuline Depot 60 mg quantity limit
    ProductSomatuline Depot (lanreotide acetate extended-release injection 60 mg/0.2 mL)
    Quantity limit1 syringe
    Day supply28 days
    Somavert quantity limit
    ProductSomavert (pegvisomant for injection 10 mg, 15 mg, 20 mg, 25 mg)
    Quantity limit30 vials
    Day supply30 days
    Somatostatin target-agent quantity-limit rule
    Standard ruleThe requested dose or quantity must not exceed the program quantity limit.
    Exception—no maximum FDA doseA higher dose may be supported when the agent has no maximum FDA-labeled dose for the indication.
    Exception—maximum FDA doseAn exception may apply when the request is within or exceeds the maximum FDA-labeled dose and clinical support is provided, including why a lower quantity of a higher strength cannot be used.
    Prior Authorization

    Renewal Approval

    For renewal, document prior approval through the plan, clinical benefit from the requested agent, specialist involvement or consultation, and absence of applicable contraindications.

    • Examples of benefit include reduced symptom severity or frequency, reduced tumor size, or normalized IGF-1 and/or growth hormone levels.
    • If used for acromegaly, confirm the requested agent will not be combined with Signifor LAR (pasireotide).
    Billing Rule

    Approval Duration and Quantity Limits

    Approvals are generally issued for 12 months. If a quantity limit applies, submit the request under the quantity-limit criteria and document any exception rationale.

    • Quantity-limit exceptions require support for the higher dose or quantity under the applicable FDA-label and program-limit conditions.
    Prior Authorization

    Initial and Renewal Prior Authorization

    Prior authorization is required for initial and renewal requests for target agents. Requests must be evaluated under the applicable initial or renewal clinical criteria.

    • Initial requests require a qualifying indication and all applicable clinical, step-therapy, specialist, and safety documentation.
    • Renewals require prior plan approval and documented clinical benefit.
    Documentation Required

    Specialist Involvement

    The prescriber must be a specialist in the area of the diagnosis, such as an endocrinologist or oncologist, or document consultation with an appropriate specialist.

    • Include the specialist's name, specialty, and relevant consultation or chart documentation.
    Billing Rule

    Authorization Duration

    Authorization length is 12 months when the applicable criteria are satisfied.

    • Submit a new request for continued treatment at renewal.
    Documentation Required

    Specialist and Safety Requirements

    For acromegaly and other covered indications, document the required disease pathway, preferred-agent history, specialist involvement, and safety review.

    • Document inadequate response to surgery or pituitary radiation, or that the patient is not a surgical candidate, or that therapy will be used with or after pituitary radiation.
    • Include growth hormone and serum IGF-1 values when inadequate response is the basis for approval.
    • Confirm no FDA-labeled contraindication to the requested agent and no prohibited pasireotide combination.
    Prior Authorization

    Acromegaly Clinical Pathway

    For acromegaly, submit the relevant clinical pathway and supporting laboratory or treatment history before requesting the target agent.

    • Document inadequate response to surgery or pituitary radiation, inability to undergo surgery, or planned use with or after pituitary radiation.
    • Document the required preferred-agent trial, exception, adjunctive use, or support for use over all preferred agents.
    • Do not combine the requested agent with Signifor LAR (pasireotide) for the requested indication.
    Step Therapy

    Non-Preferred Agent Exception

    A non-preferred agent may be approved when the record supports a qualifying exception to the preferred-agent requirement.

    • Document inadequate response, intolerance or hypersensitivity, or an FDA-labeled contraindication to the preferred agent(s).
    • For applicable strengths in acromegaly, document why the patient cannot use the preferred 120 mg agent or extended-interval dosing.
    • Support use of the non-preferred agent over the preferred agent(s) when that is the basis for the exception.
    Step Therapy

    Octreotide or Lanreotide Trial for Mycapssa

    For Mycapssa, document that the patient has responded to and tolerated treatment with octreotide or lanreotide.

    • The trial is required for the acromegaly pathway unless another applicable initial-therapy pathway applies.
    • Confirm Mycapssa will not be used with Signifor LAR (pasireotide) for the requested indication.
    Step Therapy

    Preferred-Agent Step Therapy

    Preferred-agent step therapy generally requires a trial of one preferred agent before approval of a non-preferred requested agent.

    • Document inadequate response, intolerance or hypersensitivity, FDA-labeled contraindication, or support for the requested agent over the preferred agent.
    • Chart notes are required for clinical failure, intolerance, hypersensitivity, or contraindication exceptions.
    Step Therapy

    Alternative Somatostatin Analog Trial

    For acromegaly, document the required trial of an alternative somatostatin analog when the criteria call for prior treatment with another agent.

    • Qualifying examples include Bynfezia, Somavert, Somatuline Depot/lanreotide, or Sandostatin LAR.
    • Include the treatment dates, dose, response, and reason the alternative was inadequate or could not be continued.
    Step Therapy

    Brand-Versus-Generic Step Requirement

    When the requested product is a brand with an available generic equivalent, document the applicable exception before requesting the brand product.

    • Document intolerance or hypersensitivity to the generic equivalent.
    • Document an FDA-labeled contraindication to the generic equivalent, or support for use of the brand over the generic.
    Step Therapy

    Sandostatin Prerequisite

    For applicable brand requests, document that the patient responded to and tolerated Sandostatin (octreotide) for at least 2 weeks.

    • Sandostatin LAR is identified as octreotide gluteal intramuscular injection in the policy.
    Step Therapy

    Preferred-Agent Step Requirement

    For acromegaly requests, document the applicable preferred-agent step requirement before use of a non-preferred agent.

    • Document inadequate response, intolerance or hypersensitivity, FDA-labeled contraindication, current preferred-agent adjunctive use, or support for use over all preferred agents.
    • For inadequate response, include maximally tolerated dose escalation or preexisting impaired glucose metabolism when required.
    Documentation Required

    Preferred-Agent Exception Documentation

    If the patient cannot use a preferred agent, submit chart notes explaining the exception and why the issue is not expected with the requested agent.

    • Document intolerance or hypersensitivity to one preferred agent, or an FDA-labeled contraindication to all preferred agents.
    • Alternatively, provide support for use of the requested agent over the preferred agent for the requested indication.
    Documentation Required

    Recent Requested-Agent Therapy

    Document recent use of the requested agent when seeking continuation approval.

    • The prescriber must state that treatment occurred within the past 180 days.
    • Treatment started with samples is not approvable; explain why the patient is at risk if therapy is changed.
    Documentation Required

    Clinical Diagnosis and Response

    Document the clinical diagnosis, applicable indication, treatment response or need, and the requested agent's route of administration.

    • Qualifying indications may include acromegaly, metastatic carcinoid-associated flushing or diarrhea, VIP-secreting tumor-associated watery diarrhea, another FDA-labeled indication, or a compendia-supported indication.
    • For renewal, include objective or clinically meaningful benefit.
    Documentation Required

    Specialist Involvement Documentation

    Include documentation that the prescriber is a specialist or has consulted with a specialist in the patient's diagnosis area.

    • Examples include endocrinology and oncology.
    • Provide consultation documentation when the prescribing clinician is not the relevant specialist.
    Documentation Required

    Preferred-Agent History

    Document the patient's preferred-agent treatment history before requesting a non-preferred acromegaly agent.

    • Include prior agent, dose and duration, response, intolerance, hypersensitivity, contraindication, or rationale for not using the preferred agent.
    Documentation Required

    Brand-Over-Generic Documentation

    For brand requests with a generic equivalent, document why the generic cannot be used and why the brand is clinically supported.

    • Use chart notes for intolerance, hypersensitivity, or contraindication to the generic equivalent.
    • Alternatively, provide support for the brand over the generic equivalent.
    Documentation Required

    Continuation Documentation

    For continuation requests, document recent treatment with the requested agent and the patient's risk if therapy changes; for renewal, document prior approval and clinical benefit.

    • Treatment must have occurred within the past 180 days and cannot be based solely on samples.
    • Renewal documentation should include relevant symptom, tumor, IGF-1, or growth hormone outcomes.
    Documentation Required

    Clinical Assessment

    Provide a complete clinical assessment supporting the requested agent, including diagnosis, indication, prior therapy, response, specialist involvement, and safety review.

    • Include objective laboratory or clinical findings when relevant.
    • Address preferred-agent and brand/generic requirements applicable to the request.
    Documentation Required

    Preferred-Agent History

    For acromegaly, document the patient's preferred-agent history and the basis for any exception or adjunctive use.

    • Include prior response, intolerance or hypersensitivity, contraindication, dose escalation, or rationale for use over all preferred agents.
    Documentation Required

    Continuation Documentation

    For continuation, document recent use of the requested agent and the clinical reason therapy should not be changed.

    • State that treatment occurred within the past 180 days; samples do not satisfy this requirement.
    • Include the relevant diagnosis, response, and specialist documentation.
    Documentation Required

    Strength and Dosing Rationale

    When requesting a non-preferred strength or dosing schedule for acromegaly, explain the dosing rationale and why the preferred 120 mg option or extended-interval dosing is unsuitable.

    • Document titration based on IGF-1, growth hormone levels, and/or clinical symptoms.
    • For a stable 60 mg or 90 mg dose, explain why switching to 120 mg every 6 to 8 weeks is not appropriate.
    Documentation Required

    Quantity-Limit Exception Documentation

    If the requested quantity exceeds the program limit, submit documentation supporting the applicable quantity-limit exception.

    • Address whether the dose exceeds the maximum FDA-labeled dose.
    • Explain why the quantity cannot be achieved with a lower quantity of a higher strength, when applicable.
    • Provide support for higher-dose therapy when the FDA label or program criteria permit it.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: prior_auth

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Acromegaly laboratory evidence
    Growth hormoneAbove the reference range
    Serum IGF-1Above the reference range
    Clinical contextThese laboratory findings may demonstrate inadequate response to surgical resection or pituitary radiation therapy.
    Sandostatin LAR
    Brand nameSandostatin LAR
    Active ingredientOctreotide
    AdministrationGluteal intramuscular injection
    Generic equivalent
    Policy definitionBrand, 1 = Generic Equivalent.
    Brand exceptionA brand request may qualify with intolerance or hypersensitivity to the generic, an FDA-labeled contraindication to the generic, or support for brand use over the generic.
    DocumentationChart notes are required for intolerance, hypersensitivity, or contraindication pathways.
    GEP-NETs
    AbbreviationGEP-NETs
    MeaningGastroenteropancreatic neuroendocrine tumors
    Policy pathwayGEP-NETs are identified as a diagnosis pathway in the initial evaluation criteria.
    VIP-secreting tumors
    VIPVasoactive intestinal peptide
    Tumor pathwayVIP-secreting tumors are identified as a covered indication pathway.
    Associated symptomProfuse watery diarrhea
    Preferred and non-preferred agents
    Preferred agentAn agent identified by the program as preferred.
    Listed preferred agentsLanreotide deep subcutaneous injection and octreotide gluteal intramuscular injection.
    Non-preferred exampleSomavert is identified as a non-preferred target agent.
    Eligible for continuation of therapy
    Recent treatmentThe patient must have been treated with the requested agent within the past 180 days.
    Risk if changedThe prescriber must state that the patient is at risk if therapy is changed.
    Samples excludedTreatment initiated with samples does not qualify for continuation.
    Quantity-limit exception
    Within program limitThe requested quantity is approved when it does not exceed the program quantity limit.
    Higher-dose supportIf the limit is exceeded, support is required for therapy with a higher dose when applicable.
    Alternative strengthAn exception may be supported when the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.